key: cord-0702887-a4a5bhgk
authors: Huddart, Rachel; Whirl‐Carrillo, Michelle; Altman, Russ B.; Klein, Teri E.
title: PharmGKB tutorial for pharmacogenomics of drugs potentially used in the context of COVID‐19
date: 2020-09-26
journal: Clin Pharmacol Ther
DOI: 10.1002/cpt.2067
sha: 9581d0d664f18e009939a60612a67f5b27f4d58e
doc_id: 702887
cord_uid: a4a5bhgk

Pharmacogenomics is a key area of precision medicine which is already being implemented in some health systems and may help guide clinicians towards effective therapies for individual patients. Over the last two decades, the Pharmacogenomics Knowledgebase (PharmGKB) has built a unique repository of pharmacogenomic knowledge, including annotations of clinical guideline and regulator‐approved drug labels in addition to evidence‐based drug pathways and annotations of the scientific literature. All of this knowledge is freely accessible on the PharmGKB website. In the first of a series of PharmGKB tutorials, we introduce the PharmGKB COVID‐19 portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB. This paper is intended as a resource to help users become quickly acquainted with the wealth of information stored in PharmGKB.

The COVID-19 pandemic is a rapidly evolving global emergency, which looks set to become a longterm challenge for society. Patients who are hospitalized with COVID-19 may be treated with multiple drugs, including experimental treatments and adjuvant therapies, in addition to any concomitant medications already prescribed to the patient. As such, it is vital for clinicians to be able to quickly and easily integrate as much information as possible, particularly about patient-specific factors, such as genetic variants, to optimize treatment.

The Pharmacogenomics Knowledgebase (PharmGKB) has curated pharmacogenomic (PGx) knowledge since 2000 (1) . This wealth of information about the impact of genetic variation on drug response collected from research publications, regulator-approved drug labels, clinical guidelines and other sources is freely available to all through the PharmGKB website (https://www.pharmgkb.org). Although the majority of PharmGKB content is collected and curated manually by expert scientific curators, automated annotations of PubMed abstracts and full-text articles in PubMed Central can also be accessed by users (2) .

In response to this pandemic, PharmGKB has produced a COVID-19 portal to bring together relevant pharmacogenomic resources from across the site as well as some links to external materials. The use of pharmacogenomic information should only form part of the prescribing decision-making process and must be considered alongside other factors, including concomitant medications and drug-drug interactions. This tutorial paper will guide users through the information presented in the COVID-19 portal and provide an introduction to navigating the PharmGKB website.

The PharmGKB COVID-19 portal can be accessed at https://www.pharmgkb.org/page/covid. It is currently also available via the red button displayed on the PharmGKB homepage or users can search for COVID-19 in the search box and follow the link given on the COVID-19 disease page to the

This article is protected by copyright. All rights reserved portal. The portal is updated on a regular basis and provides links to pharmacogenomic resources for relevant drugs in the following categories: For example, after clicking on the link to the fluvoxamine page, users will see that there are a number of resources available for fluvoxamine, including prescribing information and drug label annotations ( Figure 1 ). Clicking on each resource name takes the user to an overview of all of the annotations of that type.

Some experimental COVID-19 treatments do not currently have any pharmacogenomic information available, either because they are awaiting approval from the U.S. Food and Drug Administration (FDA) or because pharmacogenomic studies of these drugs have not yet been carried out. A dagger symbol next to a drug's name indicates that there is currently no pharmacogenomic information available for that drug.

This article is protected by copyright. All rights reserved

Regulator-approved drug labels can be important sources of clinical pharmacogenomic information.

To date, PharmGKB has annotated over 750 labels containing pharmacogenomic information from a number of international regulators, including the U.S. Food and Drug Administration (FDA). All drug label annotations contain a short summary followed by excerpts of relevant pharmacogenomic information taken from the label text. Some drug label annotations also have a prescribing section where genotype-based prescribing guidance from the label is recorded.

Drug label annotations are assigned a 'PGx level' by PharmGKB curators. These levels were created by PharmGKB and serve as an indication of the type of pharmacogenomic information found in the drug label. Definitions of each level are given below and further details can be found on the PharmGKB website (4).

The label states or implies that some sort of gene, protein or chromosomal testing should be conducted before using this drug. Labels which state the variant is an indication for the drug or that a test "should be" performed are also included in this category.

Testing recommended: The label states or implies that some sort of gene, protein or chromosomal testing is recommended before using this drug. PharmGKB considers labels that say testing "should be considered" or "consider genotyping or phenotyping" to be recommending testing.

Actionable PGx: The label may contain information about changes in efficacy, dosage, metabolism or toxicity due to variants or phenotypes (e.g. "poor metabolizers"). Alternatively, the label may mention contraindication of the drug in a particular subset of patients with particular variants.

However, the label does not require or recommend gene, protein or chromosomal testing Informative PGx: The label contains information stating that particular variants or phenotypes do not affect a drug's efficacy, dosage, metabolism or toxicity or that particular variants or phenotypes affect a drug's efficacy, dosage, metabolism or toxicity, but this effect is not "clinically" significant.

This article is protected by copyright. All rights reserved

The Informative PGx level is also used for labels which appears on the FDA Biomarker List but do not meet the requirements to be assigned to any of the other PGx levels. Important Pharmacogene (VIP) by PharmGKB. VIPs are known pharmacogenes, so it is more likely that variants in these genes have a pharmacogenomic impact. Users should note that fentanyl dosing is not currently recommended to be based on genotype but is monitored clinically; however

This article is protected by copyright. All rights reserved the published evidence that fentanyl response may be associated with genotype that might be informative to clinicians.

At the top of each individual clinical annotation page is a table showing all the alleles or genotypes covered by the annotation with brief summaries of the nature of the association between that specific allele or genotype and the drug. According to the evidence base for this particular clinical annotation, patients who are homozygous for the *1G allele may require a decreased dose of fentanyl compared to patients who carry at least one *1 allele. Other information about the clinical annotation, such as linked haplotypes and phenotypes, is given next to this table, while the variant annotations given as evidence for this clinical annotation are listed further down the page. By looking at the list of variant annotations, users will see that this association has been found in six separate publications.

In contrast to fentanyl, little pharmacogenomic research has been carried out on the sedative clonidine, which is only linked to two clinical annotations in PharmGKB. Both annotations have been assigned a level 3, indicating that the association may be based on only a single study, for example the annotation on rs11269124 and clonidine (PharmGKB ID 1183614793). Alternatively, level 3 annotations can show if the variant-drug pair has been evaluated in multiple studies, but the presence of conflicting evidence means that the nature of the association is not clear. This is the case for the annotation on rs5443 and clonidine, which is linked to two variant annotations which support the association and one variant annotation from a study which failed to find this association.

PharmGKB annotates genotype-based drug prescribing guidelines from CPIC, the Royal Dutch Sertraline is included in the CPIC guideline for SSRIs and is also mentioned in two guidelines from the DPWG; one with CYP2C19 which gives genotype-guided prescribing guidance, and one with CYP2D6 which states that there is no interaction between CYP2D6 and sertraline which would affect prescribing.

This article is protected by copyright. All rights reserved As mentioned above, the annotation of the CPIC guideline for sertraline includes a short video explaining the guideline and its recommendations as well as the genotype picker. Users can select any combination of alleles from the picker to access specific recommendations for that genotype.

For example, selecting the genotype *2/*2 from the picker brings up the recommendations for a CYP2C19 poor metabolizer (Figure 4 ).

Evidence-based pathway diagrams of a drug's pharmacokinetics or pharmacodynamics can help researchers to generate hypotheses about potential pharmacogenomic interactions between a gene and drug. PharmGKB currently has almost 150 freely available, drug-centered pathways. All pathways are accompanied by a written description and are interactive. Clicking on any drug or gene shown in a pathway takes the user to the PharmGKB page for that object.

Each arrow displayed on a pathway image is supported by primary scientific literature. Users can access a list of publications supporting each arrow via the Components tab, displayed on each pathway page. Pathways can also be downloaded in multiple formats, including as a PDF or in a computable GPML format.

Several drugs which have been, or are currently being, trialed as potential COVID-19 therapies have previously been associated with an increased risk of serious heart rhythm problems, such as long QT syndrome or torsades de pointes. This issue is exacerbated in patients taking concomitant medications which are also known to have a QT prolonging effect.

Drugs associated with QT prolongation or torsades de pointes are given in the 'Drugs associated with long QT syndrome and torsades de pointes' section of the PharmGKB COVID-19 portal. One such drug is the antipsychotic haloperidol. Going to the haloperidol drug page shows that three pathways

This article is protected by copyright. All rights reserved have been linked to this drug on PharmGKB; this tutorial will focus on the haloperidol pharmacokinetics and antiarrhythmic pharmacodynamics pathways.

The haloperidol pharmacokinetic pathway ( Figure 5) 

Important information on the impact of genetic variation on a patient's possible drug response can be drawn from a number of different sources, from drug labels to the scientific literature. Users can access many different pharmacogenomic resources through the PharmGKB website and the COVID-19 portal, which will continue to be updated as research into this disease and potential treatments progresses.

( 

This article is protected by copyright. All rights reserved 

Pharmacogenomics knowledge for personalized medicine

PGxMine: Text mining for curation of PharmGKB